A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Sponsor

RemeGen Co., Ltd. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05302284

Collaborator

(none)

452

Enrollment

Locations

Arms

70.5

Anticipated Duration (Months)

226

Patients Per Site

3.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Condition or Disease	Intervention/Treatment	Phase
Urothelial Carcinoma HER2-expressing	Drug: RC48-ADC Drug: Toripalimab Drug: Gemcitabine Drug: Cisplatin Drug: Carboplatin	Phase 3

Detailed Description

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study to evaluate the efficacy and safety of RC48-ADC,a recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate, in Combination With JS001,a PD-1 monoclonal antibody, for the treatment of Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

452 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing

Actual Study Start Date :

Jun 14, 2022

Anticipated Primary Completion Date :

Dec 31, 2026

Anticipated Study Completion Date :

Apr 30, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: RC48-ADC + JS001 Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).	Drug: RC48-ADC 2.5 mg/kg IV every 2 weeks Other Names: Disitamab Vedotin Drug: Toripalimab 3.0 mg/kg IV every 2 weeks Other Names: JS001
Active Comparator: Gemcitabine + cisplatin/carboplatin Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).	Drug: Gemcitabine 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle Drug: Cisplatin 70mg/m2 IV infusion on Day 1 of every 3 week cycle Drug: Carboplatin AUC=4.5, IV infusion on Day 1 of every 3 week cycle

Arm

Intervention/Treatment

Experimental: RC48-ADC + JS001

Participants will receive RC48-ADC + JS001 every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

Drug: RC48-ADC

2.5 mg/kg IV every 2 weeks

Other Names:

Disitamab Vedotin

Drug: Toripalimab

3.0 mg/kg IV every 2 weeks

Other Names:

JS001

Active Comparator: Gemcitabine + cisplatin/carboplatin

Participants will receive Gemcitabine + cisplatin or carboplatin every 3 weeks (Q3W) for maximum 6 weeks or until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

Drug: Gemcitabine

1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle

Drug: Cisplatin

70mg/m2 IV infusion on Day 1 of every 3 week cycle

Drug: Carboplatin

AUC=4.5, IV infusion on Day 1 of every 3 week cycle

Outcome Measures

Primary Outcome Measures

Progression-free survival (PFS), evaluated by independent review committee [Up to approximately 3 years]
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by independent review committee according to the RECIST 1.1 standard.
Overall survival (OS) [Up to approximately 3 years]
Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

Secondary Outcome Measures

Objective remission rate (ORR) [Up to approximately 3 years]
The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).
Progression-free survival (PFS), evaluated by the investigator [Up to approximately 3 years]
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.
Duration of relief (DOR) [Up to approximately 3 years]
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death
Disease control rate (DCR) [Up to approximately 3 years]
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Expected survival ≥12 weeks.
Locally advanced unresectable or metastatic UC with histopathological confirmation, including UC originating from the renal pelvis, ureters, bladder, or urethra.
Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:

Participants that received neoadjuvant chemotherapy with recurrence >6 months from completion of therapy are permitted; Participants that received adjuvant chemotherapy following cystectomy with recurrence >6 months from completion of therapy are permitted.

At least one measurable lesion based on RECIST version 1.1
HER2-expressing status determined by the central laboratory to be IHC 1+, 2+ or 3+.
ECOG performance status score: 0 or 1.
Adequate cardiac, bone marrow, hepatic, renal, and coagulation functions.

Exclusion Criteria:

Known hypersensitivity to RC48-ADC or Toripalimab or any of its components.
History of major surgery within 4 weeks of planned start of trial treatment.
Toxicity from a previous treatment has not returned to Grade 0-1.
Prior ADCs or PD-1/PD-L1 inhibitor therapy.
Active central nervous system (CNS) metastases.
Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
History of other malignancy within the previous 5 years, except for low-risk localized prostate cancer, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.
Other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, or uncontrolled diabetes.
Active autoimmune diseases that require systemic therapy over the past 2 years. Replacement therapies (such as thyroxine, insulin, or physiological replacement of glucocorticoids due to renal or pituitary deficiency) are allowed.
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.